H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRX – Research Report) today and set a price target of $19.00. The company's shares closed last Tuesday at $2.01, close to its 52-week low of $1.93. According to TipRanks.com, Pantginis ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.7% and a 24.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Biolinerx.
https://www.tipranks.com/news/blurbs/biolinerx-blrx-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
BioLineRx (NASDAQ:BLRX)
Gráfico Histórico do Ativo
De Dez 2022 até Jan 2023 Click aqui para mais gráficos BioLineRx.
BioLineRx (NASDAQ:BLRX)
Gráfico Histórico do Ativo
De Jan 2022 até Jan 2023 Click aqui para mais gráficos BioLineRx.